These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36568963)

  • 21. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
    Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
    McMullen M; Karakasis K; Madariaga A; Oza AM
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32560564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
    Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of PARP inhibitors in breast cancer.
    Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
    Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
    Gill SJ; Travers J; Pshenichnaya I; Kogera FA; Barthorpe S; Mironenko T; Richardson L; Benes CH; Stratton MR; McDermott U; Jackson SP; Garnett MJ
    PLoS One; 2015; 10(10):e0140988. PubMed ID: 26505995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
    Helleday T
    Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of PARP inhibitor resistance in ovarian cancer.
    Kubalanza K; Konecny GE
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):36-41. PubMed ID: 31815769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
    De Lorenzo SB; Patel AG; Hurley RM; Kaufmann SH
    Front Oncol; 2013 Sep; 3():228. PubMed ID: 24062981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
    Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic Induction of BRCAness in
    Abbotts R; Dellomo AJ; Rassool FV
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.